ArticleThe archives of bone and joint surgery2019
Various Dosages of BMP-2 for Management of Massive Bone Defect in Sprague Dawley Rat.
Article in The archives of bone and joint surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Dose-Dependent Osteoinduction by rhBMP-2-Loaded β-Tricalcium Phosphate Scaffolds in Rabbit Critical-Sized Calvarial Defects: Histological, Histomorphometric, CD31 Immunohistochemical Evaluation.International journal of molecular sciences · 2026Article
- Optimizing the osteo-immunomodulatory balance: threshold-saturation effects of BMP-2-loaded allografts in the Masquelet's induced membrane technique (MIMT).Frontiers in bioengineering and biotechnology · 2026Article
- Efficacy of Three-Dimensional Bioactive Composites in Long Bone Repair with Photobiomodulation.Materials (Basel, Switzerland) · 2025Article
- Biological Behavior of Bioactive Glasses SinGlass (45S5) and SinGlass High (F18) in the Repair of Critical Bone Defects.Biomolecules · 2025Article
- Biofunctional response of a synthetic ceramic of 99.9% tricalcium phosphate associated with a heterologous fibrin biopolymer and infrared photobiomodulation.Frontiers in bioengineering and biotechnology · 2025Article
- Effectiveness of the Association of Fibrin Scaffolds, Nanohydroxyapatite, and Photobiomodulation with Simultaneous Low-Level Red and Infrared Lasers in Bone Repair.Materials (Basel, Switzerland) · 2024Article
- Recent advancement in vascularized tissue-engineered bone based on materials design and modification.Materials today. Bio · 2023Review
- Moderate-Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein-2.Advanced healthcare materials · 2023Article
- Tissue Bioengineering with Fibrin Scaffolds and Deproteinized Bone Matrix Associated or Not with the Transoperative Laser Photobiomodulation Protocol.Molecules (Basel, Switzerland) · 2023Article
- Orthobiologics: Current role in Orthopedic Surgery and Traumatology.The archives of bone and joint surgery · 2022Review
- Engineering stem cells to produce exosomes with enhanced bone regeneration effects: an alternative strategy for gene therapy.Journal of nanobiotechnology · 2022Article
- 3D-printed scaffold combined to 2D osteoinductive coatings to repair a critical-size mandibular bone defect.Materials today. Bio · 2021Article
- Article
- BMP and TGFβ use and release in bone regenerationTurkish journal of medical sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBMP-2 has a crucial role in the treatment of extensive bone defect. However, data about the optimal dosage of BMP-2 in the massive bone defect casesis rare.
methodsTwenty-five SD rats were randomly allocated into a control group of hydroxyapatite (HA) alone (Group I), HA+BMP-2 1µg/mL (Group II), HA+BMP-2 5 ug/mL (Group III), HA+BMP-2 10 µg/mL (Group IV), and HA+BMP-2 20 ug/mL (Group V). Osteotomies were performed in each group with 10 mm bone defect in the right femur, followed by fixation and filling the defect. The fracture healing was evaluated by histomorphometry, and radiographs using RUST score.
resultsWe found there were significant differences in the mean total area of callus between the treatment groups (
conclusionThe administration of BMP-2 stimulates the formation of bone bridging in a massive bone defect. The bone bridging filling massive bone defect depends on the dose or concentration of BMP-2. Administration of an optimal dose (10 µg/mL) of BMP-2 demonstrates better result than lower or higher dose for massive bone defect healing in SD rate.
Indexed as
Identifiers
31970254PMC6935524W2944530275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.